Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iptacopan in complement 3 glomerulopathy (Japan)
jRCT2041210082Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2021
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in Complement 3 glomerulopathy (C3G) comparing LNP023 (iptacopan) with Placebo to LNP023 (2 arms). Primary endpoint: Change from baseline in eGFR at 6 months. Started Oct 2021; status: active, not recruiting.
02
Drugs
Iptacopan
03
Conditions
Complement 3 glomerulopathy (C3G)
Beyond the preview
Go deeper on jRCT2041210082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210082.